Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Net Change in Cash : ¥-1,668 Mil (TTM As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Shanghai Fosun Pharmaceutical (Group) Co's Net Change in Cash for the three months ended in Dec. 2023 was ¥-580 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was ¥-1,668 Mil.

Shanghai Fosun Pharmaceutical (Group) Co Net Change in Cash Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Net Change in Cash Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

1,109.37

-959.49

-873.79

4,710.35

-1,667.68

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															476.79	950.68	-61.37	-1,977.21	-579.77

Shanghai Fosun Pharmaceutical (Group) Co Net Change in Cash Calculation

Shanghai Fosun Pharmaceutical (Group) Co's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	3414.217	+	-3819.29	+	-1336.25	+	73.645
	=	-1,668

Shanghai Fosun Pharmaceutical (Group) Co's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 952.577 + -534.997 + -939.67 + -57.683

= -580

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1,668 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (SHSE:600196) » Definitions » Net Change in Cash

Comparable Companies

SZSE:000963 SZSE:002001 SZSE:000999 SHSE:600085 SHSE:688506 SHSE:600332 SZSE:000661 SZSE:000423 SHSE:600566 SHSE:600079 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX

Traded in Other Exchanges

SFOSF:USA 02196:Hong Kong 08HH:Germany

Address

No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website

https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Headlines

No Headlines